Principal Director, Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi
Part 11 of 12 in Recent Trends in Surgical Oncology - Breast and GI Oncology
Personalised Cancer Treatment, Immunotherapy and CAR-T Cell Therapy
September 6, 2026
Dr. Jain was asked how close oncology really is to the kind of personalised, genetically-guided cancer treatment that has been generating headlines. His answer: already underway, but with a long way still to go.
Matching the drug to the tumour
He compared it to urine culture and sensitivity testing for a urinary infection: molecular sequencing of a tumour identifies which drug the cancer cells are actually sensitive to, so treatment is not one-size-fits-all. Lung cancer has already seen a sea change this way, and a single daily tablet is now available for metastatic pancreatic cancer, previously among the most lethal diagnoses in oncology. Molecular analysis can, in some cases, substitute targeted therapy or immunotherapy for chemotherapy in systemic treatment, and can allow radiosensitising drugs to reduce the radiation dose needed. Surgery, however, remains the mainstay and cannot be replaced for localised disease.
Immunotherapy and CAR-T cell therapy explained
Asked to explain the underlying principle of CAR-T cell therapy, Dr. Jain described it as retraining the body's own immune cells, which weaken when cancer is present, to recognise and fight the cancer again, rather than the drug killing the tumour directly. He closed this thread on a hopeful note: a cervical cancer vaccine already exists, and he expects a breast cancer vaccine within two to three years and vaccines against most cancers within ten to fifteen years, a shift that would put cancer alongside diseases like polio that have been made rare through prevention.
This article is based on a Jivo Masterclass session conducted by Dr. Rajesh Kumar Jain, Principal Director, Surgical Oncology, BLK-Max Cancer Centre, New Delhi. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
Looking for a surgical oncology consultation or a second opinion? Get in touch with the Jivo team
This guide is based on a live Jivo Masterclass: Dr. Rajesh Kumar Jain taught doctors across Africa on September 6, 2026.
FROM THE LIVE Q&A
Jivo Doctor Partner (name unclear from transcript)
The principle behind CAR-T cell therapy is using the body's own cells and modifying immunity to attack cancer. Could the body be developing cancers that our own immunity handles without it becoming a concern, with only cases beyond our immune capacity becoming a real concern for cancer doctors?
Dr. Rajesh Kumar Jain
CAR-T cell therapy, and immunotherapy generally, works on a simple concept: our own immune cells are competent enough to fight infection and cancer, but whenever cancer is present, immunity goes down. Immunotherapy retrains the remaining immune cells to fight again, rather than killing the tumour directly. The drugs make our own immunity more competent, cells that were lying idle are retrained and made to recognise the cancer as the enemy, and then they go and fight it.
Book a Consultation with Dr. Rajesh Kumar Jain
Book on WhatsAppOr message us on WhatsApp: +91 98182 98669
Frequently Asked Questions
A question from Dr. Innocent Nzili in Kenya: why do some dormant cancer cells survive initial treatment and hide in the body for years before suddenly reactivating to cause a deadly recurrence?▼
The exact mechanism is still not fully known. But one clear factor is genetic aberrations that occur over time because of environmental exposure: if a patient achieves a cure but resumes alcohol or smoking, the damage caused by tobacco or other carcinogens affects the DNA again and dormant cells can get reactivated. That is one reason recurrence happens, though most of the time the actual mechanism is not known.
In sub-Saharan Africa, most countries do not have a PET-CT scanner. What alternatives can a doctor use to get a near-accurate estimation of disease stage without one?▼
For bone metastasis, use a nuclear bone scan; if that is unavailable, do a skeletal survey, plain X-rays of the spine, ribs, pelvis and limbs. For liver metastasis, a CT abdomen substitutes for PET, and an ultrasound is a fair investigation if CT is also unavailable. For the lungs, a CT chest is the alternative, and a plain chest X-ray is fair enough if CT is not available. Also check the uterus and ovaries with a pelvis ultrasound in every breast cancer patient, to rule out Krukenberg tumours. Ultrasound and X-rays are available almost everywhere in the world, and while less precise than PET-CT, this combination is enough to establish metastatic staging.
Many cancer cases referred from outside India are far advanced by the time they reach surgical oncology, with the objective becoming palliative rather than curative. How can doctors be made more aware of the need for timely referral?▼
Diagnosing cancer early, at stage 1 or 2, translates into cure; stage 4 offers very minimal chances of cure for any cancer. Where facilities and education are limited, the solution has three parts: awareness, awareness, and awareness, among doctors, the public and government. Over almost 30 years of practice, running thousands of community cancer-awareness camps across India, Nepal, Bhutan and Bangladesh with NGO partners has produced a real shift: around 1997, 75-80% of patients presented in stage 3 or 4; today in metropolitan India, around 60% present at an early stage.
Beyond breast cancer, where awareness is already relatively good, when should a general practitioner without easy access to specialists suspect cancers like liver, gastric or lung cancer?▼
A non-healing mouth ulcer of 15-20 days in a smoker warrants a biopsy for oral cancer. A voice change over six weeks or dysphagia should raise suspicion. A cough not responding to 4-5 weeks of anti-tuberculosis treatment needs a chest X-ray. Early satiety, feeling full after a much smaller meal than usual, is a classic warning sign for stomach cancer. Unexplained weight loss or easy fatiguability should raise suspicion of pancreatic or liver cancer, and every jaundice patient should get at least an ultrasound rather than being assumed to have hepatitis. A change in bowel habit should prompt investigation for colorectal cancer, and around 30% of bleeding per rectum, usually assumed to be piles, is actually cancer. A painless testicular swelling should not be assumed to be a hydrocele without an ultrasound, and an enlarging soft tissue lump assumed to be a lipoma should get an FNAC to rule out sarcoma.
A patient case from Dr. Alem in Ethiopia: right breast masses, two in number near the periareolar region, 3cm and 4cm, attached to each other by fibrous tissue, with core needle biopsy showing invasive ductal carcinoma. How should this proceed, and is breast conservation surgery possible?▼
Complete staging first, chest X-ray, abdominal ultrasound and a skeletal survey or bone scan, to know whether there is metastasis. If there is no distant metastasis and ER/PR is positive, go for surgery, but because this is periareolar, central-quadrant disease, mastectomy with axillary clearance is the better option over breast conservation, even if the rest of the breast looks normal on mammography. If metastasis is found instead, start with chemotherapy.
What is personalised cancer treatment?▼
Molecular sequencing of a tumour to identify which drug it is actually sensitive to, similar in concept to culture and sensitivity testing for infections, so treatment is matched to the individual tumour rather than one-size-fits-all.
How does CAR-T cell therapy work, in simple terms?▼
It retrains the body's own immune cells, which weaken when cancer is present, to recognise and actively fight the cancer again, rather than the drug killing the tumour directly.
In This Series: Recent Trends in Surgical Oncology - Breast and GI Oncology
- 1.Recent Trends in Surgical Oncology
- 2.Breast Cancer Diagnosis, Staging and Molecular Workup
- 3.Breast Cancer Treatment: From Early-Stage to Metastatic and Oligometastatic Disease
- 4.Breast Cancer Surgery: Conservation vs Mastectomy and Axillary Management
- 5.Staging Cancer Without a PET-CT: Practical Alternatives for Resource-Limited Settings
- 6.Organ-by-Organ Red Flag Symptoms for Early Cancer Detection
- 7.Timely Referral and Awareness: Closing the Gap Between Early and Late-Stage Diagnosis
- 8.Case Discussion: Bilateral Periareolar Breast Masses and Bloody Nipple Discharge
- 9.Multidisciplinary Cancer Care: Tumour Boards, Robotic Surgery and Patient Outcomes
- 10.Circulating Tumour DNA and the Biology of Cancer Recurrence
- 11.Personalised Cancer Treatment, Immunotherapy and CAR-T Cell Therapy
- 12.Fellowship and Observership Pathways in Surgical Oncology at BLK-Max